OncoFusion is a privately owned company with a goal to discover and develop the next generation of personalized therapeutics for patients with genetically defined cancers. According to their website, their BET Bromodomain Inhibitor program is their most advanced drug development program. They published this BET bromodomain/mCRPC paper in Molecular Cancer Research early last year, and two of the authors are co-founders of OncoFusion and one author is a consultant for OncoFusion. They also published a 2014 paper in Nature in this area.

I bring this up because back in 2014, OncoFusion licensed some of their BET bromodomain inhibitors to Medivation (the developer of enzalutamide). But less than two years later in January 2016 OncoFusion reacquired the rights to their BET bromodomain inhibitors from Medivation prior to Pfizer buying Medivation.

Was this a missed opportunity by Medivation to lock up a BET inhibitor program for mCRPC/enzalutamide, now that both Gilead and Zenith are pushing ahead in this area? 

Did Pfizer just miss the train leaving the station when OncoFusion reacquired the rights to its BET bromodomain inhibitors a few months prior to Pfizer buying Medivation?

Hmmmmmm.

BearDownAZ